Prudential Financial
CRSP icon

Prudential Financial’s CRISPR Therapeutics CRSP Stock Holding History

Prudential Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$882K Buy
18,535
+8,955
+93% +$472K ﹤0.01% 1651
2025
Q4 		$502K Buy
9,580
+1,045
+12% +$62.6K ﹤0.01% 1829
2025
Q3 		$553K Buy
8,535
+3,525
+70% +$202K ﹤0.01% 1898
2025
Q2 		$237K Buy
+5,010
New +$194K ﹤0.01% 2162

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Prudential Financial's CRSP Position: Q1 2026 in Review

Prudential Financial increased its CRISPR Therapeutics (CRSP) stake by 93% in Q1 2026, buying an estimated $472K and bringing the position to 18,535 shares worth $882K. The position accounts for ﹤0.01% of the portfolio, ranked #1651.

Prudential Financial first reported a position in CRSP in Q2 2025 and has held it in 4 quarters since. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Prudential Financial held 18,535 shares of CRISPR Therapeutics worth $882K as of Q1 2026.
  • Prudential Financial bought 8,955 CRISPR Therapeutics shares in Q1 2026, an estimated $472K.
  • CRISPR Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #1651 holding.
  • Prudential Financial first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.